Frankfurt-am-Main, Germany

Thomas Langer

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations by Thomas Langer

Introduction

Thomas Langer is a prominent inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic proteins. With a total of seven patents to his name, Langer's work is recognized for its potential impact on medical treatments.

Latest Patents

Langer's latest patents include groundbreaking inventions such as FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides. These inventions provide improved physico-chemical properties for therapeutic applications. Additionally, he has developed multispecific antibodies facilitating selective light chain pairing. This innovation allows for the desired chain pairing to be selected, enhancing the efficacy of bispecific antibodies.

Career Highlights

Langer is currently employed at Sanofi, a leading global biopharmaceutical company. His work at Sanofi has allowed him to collaborate with other experts in the field and contribute to the advancement of medical science. His innovative approach and dedication to research have positioned him as a key figure in the biotechnology sector.

Collaborations

Some of Langer's notable coworkers include Christian Lange and Ercole Rao. Their collaborative efforts have further enriched the research environment and fostered the development of new therapeutic solutions.

Conclusion

Thomas Langer's contributions to biotechnology through his patents and work at Sanofi highlight his role as an influential inventor. His innovative solutions have the potential to transform medical treatments and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…